A 16-week, double-blind, placebo-controlled, randomised, parallel-group, multicentre, international study to evaluate the efficacy and safety of 40 mg/day KW-6002 (istradefylline) and that of entacapone versus placebo as treatment for Parkinson's disease in patients with motor response complications on levodopa therapy
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Istradefylline (Primary) ; Entacapone
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 07 Jun 2011 New source identified and integrated (European Clinical Trials Database).
- 27 Nov 2005 New trial record.